June 15, 2018
Announcement no. 11

In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to issue 900,000 new warrants to BioPorto’s Chief Financial Officer, Ole Larsen, in connection with his employment in BioPorto A/S.

The issuance of new warrants will support the company's long-term goals and establish a performance-based remuneration reflecting the company's and shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 3.11 per share. Warrants will be exercisable from June 15, 2020 – June 14, 2023. Within the exercise period, warrants can be exercised within ordinary trading windows.

Conditions for cancellation of all warrants apply in case the Company does not achieve FDA approval of The NGAL Test™. The program also includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of e.g. takeover bid, resolution and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association on www.bioporto.com under Investor Relations> Governance> Company Articles.

The total number of shares that the holder of warrants will be able to subscribe upon exercise of the warrants, are 900,000. The theoretical market value of the allocations of warrants amounts to DKK 575,475. The calculation is based on the Black-Scholes formula using an interest rate of -0.556% and the historical volatility of BioPorto A/S' shares of 24 months calculated to 37.6%.

For further information, please contact:

Thomas Magnussen, Chairman of the Board
Gry Husby Larsen, General Counsel
Telephone +45 4529 0000, e-mail investor@bioporto.com

About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

Attachment